<DOC>
	<DOCNO>NCT01416025</DOCNO>
	<brief_summary>This prospective , multicenter , randomize trial study therapeutic drug monitoring ( TDM ) voriconazole among patient invasive mould infection ( IMI ) . The primary objective study assess effect prospective voriconazole TDM composite adverse event ( AE ) clinical response .</brief_summary>
	<brief_title>A Trial Comparing Efficacy Safety Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing</brief_title>
	<detailed_description>This prospective study patient receive voriconazole treatment IMI ( proven , probable , possible EORTC/MSG definition ) , zygomycosis . Patients randomize receive either standard dose dose base TDM , stratify whether initial voriconazole therapy PO IV . Assessment outcomes make 42 day start voriconazole . An additional follow safety reporting perform 4weeks completion voriconazole The patient randomize : - Prospective TDM : voriconazole dose adjust base per protocol obtain TDM level , - Standard dosing : standard dos voriconazole use . In prospective TDM arm , voriconazole TDM perform real time site result report treating physician dose adjustment . All effort take obtain result within 24 hour blood sample collection . In standard dosing arm , blood sample collect , store , batch voriconazole level test retrospectively . Voriconazole plasma level measure validated high performance liquid chromatography ( HPLC ) assay detailed . Voriconazole trough level perform Day Baseline/Screening , 5 , 14 , 28 , 42 . Voriconazole peak level measure Day 5 . Trough voriconazole level obtain case event , define suspect drug-associated toxicity and/or clinical failure . Assessment AEs patient monitor study response treatment assess . The composite overall AE/clinical failure assess day 42 .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Indication voriconazole administration : proven , probable , possible IMI , exclude zygomycosis ( base revise EORTC/MSG consensus definition ) [ De Pauw , Clin Infect Dis . 2008 ; 46:1813 ] . Male female â‰¥12 year age . Evidence personally sign date informed consent document accordance local regulatory legal requirement indicate subject ( legally acceptable representative ) inform pertinent aspect study . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Known history allergy , hypersensitivity serious reaction azole antifungal . Patients aspergilloma allergic bronchopulmonary aspergillosis ( ABPA ) . Patients chronic invasive aspergillosis duration symptom radiological find 4 week prior study entry . Patients receive discontinue follow drug least 24 hour prior randomization : terfenadine , pimozide quinidine ( possibility QT prolongation ) , St John 's wort preparation . Patients receive follow medication : sirolimus , rifampin , rifabutin , carbamazepine , long act barbiturate ( e.g. , phenobarbital , mephobarbital ) , ritonavir , efavirenz , ergot alkaloid ( e.g. , ergotamine , dihydroergotamine ) . Receipt 5 day voriconazole treatment prior enrollment . Receipt 7 day systemic antifungal treatment current episode IMI . Severe liver dysfunction ( defined total bilirubin , AST , ALT , alkaline phosphatase &gt; 5x upper limit normal ) . Local laboratory result may use qualify individual enrollment . Patients condition , opinion investigator , could affect patient safety , preclude evaluation response , make unlikely propose course therapy complete . Patients already participate trial within last 30 day . Patients high likelihood death due factor unrelated IA ( e.g. , due relapse malignancy , severe GVHD , underlie disease , etc . ) within 30 day follow planned enrollment ( investigator 's discretion ) . Patients weigh &lt; 45 &gt; 120 kg , respectively , upon enrollment . If patient ' weight beyond limit upon serial assessment study period , study monitor contact decision keep withdraw subject study make .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Voriconazole</keyword>
	<keyword>Therapeutic drug monitoring</keyword>
	<keyword>Hematopoietic stem cell transplant</keyword>
	<keyword>Hematologic malignancy</keyword>
	<keyword>Invasive mould infection</keyword>
</DOC>